Novartis' R&D expenditure as a percent of revenue 2004-2023
This statistic represents Swiss-based pharmaceutical company Novartis' expenditure on research and development, from 2004 to 2023, as a percentage of revenue. In 2023, research and development expenditure accounted for about one quarter of Novartis' total revenue. The high percentage was driven by the spin-off of Novartis' generics division Sandoz during that year.